Page last updated: 2024-11-04

tilisolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5474
CHEMBL ID1742457
CHEBI ID135291
SCHEMBL ID49651
MeSH IDM0111347

Synonyms (22)

Synonym
(+-)-4-(3-(tert-butylamino)-2-hydroxypropoxy)-2-methylisocarbostyril
tilisololum [latin]
tilisolol [inn]
1(2h)-isoquinolinone, 4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-2-methyl-
tilisolol
CHEBI:135291
L004336
D08598
85136-71-6
tilisolol (inn)
4-[3-(tert-butylamino)-2-hydroxypropoxy]-2-methylisoquinolin-1-one
unii-quf41mf56g
tilisololum
quf41mf56g ,
tilisolol [who-dd]
tilisolol [mi]
CHEMBL1742457
AKOS025311458
SCHEMBL49651
DTXSID0043846
Q7802167
NCGC00538146-01

Research Excerpts

Overview

Tilisolol is a beta-blocking agent with vasodilatory properties. It was recently shown to possess a potassium (K+) channel opening activity.

ExcerptReferenceRelevance
"Tilisolol is a beta-blocking agent with vasodilatory properties that was recently shown to possess a potassium (K+) channel opening activity. "( Tilisolol hydrochloride dilates coronary arteries through an ATP-sensitive K(+)-channel opening mechanism in dogs.
Kinoshita, M; Liu, Q; Nakae, I; Takahashi, M; Takaoka, A, 1996
)
3.18

Pharmacokinetics

ExcerptReferenceRelevance
" On the basis of these results, an in vivo pharmacokinetic model was developed for estimation of penetration parameters."( Characterization of ocular pharmacokinetics of beta-blockers using a diffusion model after instillation.
Ichikawa, M; Mukai, T; Nakamura, J; Nakashima, M; Nishida, K; Sasaki, H; Yamamura, K, 1999
)
0.3
"The ocular absorption of timolol and tilisolol was characterized using an in vivo pharmacokinetic model and in vivo penetration parameters."( Characterization of ocular pharmacokinetics of beta-blockers using a diffusion model after instillation.
Ichikawa, M; Mukai, T; Nakamura, J; Nakashima, M; Nishida, K; Sasaki, H; Yamamura, K, 1999
)
0.58
"We previously developed an in vivo pharmacokinetic model that accounts for the corneal diffusion in albino rabbits and predicts the concentration of beta-blockers in the anterior segments."( Pharmacokinetic prediction of the ocular absorption of an instilled drug with ophthalmic viscous vehicle.
Ichikawa, M; Mukai, T; Nakamura, J; Nakashima, M; Nishida, K; Sasaki, H; Yamamura, K, 2000
)
0.31

Bioavailability

ExcerptReferenceRelevance
" The viscous vehicle decreased the absorption rate constant of the drug from the injection site to systemic circulation compared with the buffer solution."( Topical delivery system of ophthalmic drugs by periocular injection with viscous solution.
Ichikawa, M; Kashiwagi, S; Mukai, T; Nakamura, J; Nakashima, M; Nishida, K; Sasaki, H, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
isoquinolinesA class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (26.92)18.7374
1990's11 (42.31)18.2507
2000's8 (30.77)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.87 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.85%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (3.85%)4.05%
Observational0 (0.00%)0.25%
Other24 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]